ENTITY
Cathay Biotech

Cathay Biotech (688065 CH)

37
Analysis
MaterialsChina
Cathay Biotech Inc. engages in synthetic biology, producing new materials on an industrial scale through bio-manufacturing. The Company focuses on polyamide industry's value chain covering biological long-chain dibasic acid, bio-based pentane diamine, bio-based polyamide, and more. Cathay Biotech markets its products worldwide.
more
Refresh

CSI300 Index Rebalance Preview: Potential Adds Outperforming Despite ETF Inflows

The adds have outperformed the deleted by over 10% in the last month. Coming up to the end of the review period, there could be further positioning.

Logo
898 Views
Share
bullishZOZO Inc
10 Mar 2024 05:50

Index Rebalance & ETF Flow Recap: NKY, ASX, CSI300, A50, STTF, LowVol30, Value Up

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
829 Views
Share
08 Feb 2024 10:02

China ETF Inflows & Impact: Concentrated, Then Diversified; Central Huijin Steps Up

Nearly US$37bn has flowed into mainland China listed ETFs since 2 January and could be driven by the National Team supporting the market. Central...

Logo
438 Views
Share
28 Jan 2024 05:30

Index Rebalance & ETF Flow Recap: CSI300, CSI500, SSE50, ChiNext, KOSPI200, Renesas, IDX30/LQ45

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
514 Views
Share
bullishKunlun Tech
23 Jan 2024 06:20

CSI500 Index Rebalance Preview: High Turnover & Big Flow

We forecast 50 changes in June leading to one-way turnover of 9.1% and one-way trade of CNY 5.34bn. There will be over 1x ADV to trade on 28...

Logo
512 Views
Share
x